Cartesian Therapeutics CTO Metin Kurtoglu to depart May 1; will serve as consultant through April 2026

Cartesian Therapeutics, Inc.

CTO Metin Kurtoglu's employment ends May 1, 2025; consulting agreement runs through April 30, 2026.
Separation agreement includes 12 months salary, pro-rated bonus eligibility, and accelerated vesting of equity awards granted Jan 2, 2024.
Release of claims upon receipt of severance benefits as per employment agreement dated March 28, 2024.
No replacement named; Dr. Kurtoglu will remain in advisory role under consulting terms.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Metin Kurtoglu

Chief Technology Officer

RNAC · Cartesian Therapeutics, Inc.

Effective: 2025-05-01
Filed: April 29, 2025, 7:59 PM ET

Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Metin Kurtoglu departed as Chief Technology Officer at Cartesian Therapeutics, Inc..

Action: employment will end
Role: Chief Technology Officer

Exact text from the filing

Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025

View on SEC.gov

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-25-000077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.